The 17-country report is designed and developed in a way that it comprises of the current market scenarios and taking individual tests. This report will help the already existing material suppliers to forecast and project the future scopes and possibilities for the opportunities arising in the different seas of the market in Automated Microbiology in the upcoming five years. The report examines key trends, reviewing current and emerging assets, analyzing potential applications of innovative diagnostic technologies, forecasting volume, and sales for 100 molecular diagnostics, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic procedures.
As the level of automation is lagging behind than major clinical laboratory segments, such as chemistry and hematology, the slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems and issues. Once the technology was developed and the diffusion of automated microbiology systems was done, it did not match that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. It is still believed by some laboratorians that current instrumentation is not the ultimate technology and expect better automation on the horizon.
Diagnostics industry executives will be assisted by this comprehensive 17-country survey, as well as companies that are planning to diversify into the dynamic and rapidly expanding microbiology market. They will work towards evaluating emerging opportunities and developing effective business strategies.